Mechanical heart pump can reverse heart failure

August 20, 2001

DALLAS, Aug. 21 - Left ventricular assist devices, or LVADs, used to mechanically pump blood through the hearts of individuals with heart failure as they await transplantation, can reverse reduced heart muscle performance, researchers report in today's Circulation: Journal of the American Heart Association.

This finding sheds new light on the commonly held theory that heart failure is an end-stage disease, with the only option for patients being a heart transplant, say the study researchers.

The study was among the first to look at beta-adrenergic receptor density and inotropic responsiveness to beta-adrenergic stimulation - the mechanisms that control the heart's ability to contract in times of stress. In individuals with heart failure, both functions are blunted.

Researchers found that with the aid of an LVAD, these hallmarks of heart failure are reversible.

An LVAD is a mechanical pump-type device that is surgically implanted to augment the heart's pumping ability. It can "buy time" for an individual waiting for a heart transplant and is often referred to as a "bridge to transplant."

Researchers obtained non-failing human hearts from 15 organ donors whose hearts were unsuitable for transplantation but who had no history of cardiac disease. They obtained failing human hearts from 23 transplant patients who had not been supported with an LVAD and 19 patients who had been supported with an LVAD. The researchers used two methods in the study. They dissected muscle tissue from the hearts to compare cardiac muscle contractility at baseline and after stimulation by the drug isoproterenol. They also measured the density of beta-adrenergic receptors in non-failing human hearts and failing human hearts with or without LVAD. Results showed a significant increase in the response to beta-adrenergic stimulation after LVAD and an increased density of beta-adrenergic receptors, which indicate improved muscle performance.

Nearly 5 million Americans are living with heart failure. There are about 550,000 new cases diagnosed each year while the number of heart donors remains unchanged, according to the researchers. They say that more studies need to be done in order to determine whether the LVAD or other medical or surgical therapies could replace the need for heart transplants.
Monique L. Ogletree-Hughes, Ph.D., post-doctoral fellow, The Cleveland Clinic Foundation, Cleveland, Ohio; 216-445-5046;

CONTACT: For journal copies only,
please call: (214) 706-1396
For other information, call:
Carole Bullock: (214) 706-1279
Bridgette McNeill: (214) 706-1135

American Heart Association

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to